Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile
Anup Kasi MD MPH

@anup_kasi

GI medical oncologist and researcher @ Univ of Kansas

ID: 939338754715766785

calendar_today09-12-2017 03:39:46

509 Tweet

1,1K Takipçi

570 Takip Edilen

Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile Photo

🎉 Wow, congrats to my amazing mentee for his work on evaluating real-world results of PRRT in GEP-NETs! The significant findings for a unique patient subset are intriguing . So proud to be your mentor, Stijn Hentzen, MD ! 🙌 NET Research Foundation #NETCancer #Carcinoid #GEPNETs #NETsResearch

Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile Photo

Had an amazing experience at #GDUGI2023! Engaging in stimulating debate-style discussions was a privilege. Huge thanks to Dr. Cathy Eng and Great Debates for the invitation to share my thoughts! 🗣️🙌

Had an amazing experience at #GDUGI2023! Engaging in stimulating debate-style discussions was a privilege. Huge thanks to <a href="/CathyEngMD/">Dr. Cathy Eng</a> and <a href="/GreatDebatesCME/">Great Debates</a> for the invitation to share my thoughts! 🗣️🙌
Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile Photo

We need to think out of the box. Thank you Let's Win Pancreatic Cancer 💜 for highlighting this novel clinical trial that I’m leading with misetionamide GP-2250 in #PancreaticCancer by Panavance #pancsm #PancChat PanCAN letswinpc.org/research/clini…

Joe Bennett MD (@joebennettmd) 's Twitter Profile Photo

Pancreatic cancer moving the needle on improved outcomes, every bit counts for these patients. With 5 year OS of 13%, more studies needed. NAPOLI3 trial for journal club today with Anup Kasi MD MPH @smullangiMd #PancreaticCancer #JournalClub

Pancreatic cancer moving the needle on improved outcomes, every bit counts for these patients. With 5 year OS of 13%, more studies needed. NAPOLI3 trial for journal club today with <a href="/anup_kasi/">Anup Kasi MD MPH</a> @smullangiMd #PancreaticCancer #JournalClub
KU Cancer Center (@kucancercenter) 's Twitter Profile Photo

#ASCO24 - At 1:30 pm, head over to Hall A where Anup Kasi MD MPH and the @KUCancerCenter team are presenting “Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial.”

#ASCO24 - At 1:30 pm, head over to Hall A where <a href="/anup_kasi/">Anup Kasi MD MPH</a> and the @KUCancerCenter team are presenting “Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial.”
Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile Photo

🏁 Excited to share the news that we have completed full enrollment of #PancreaticCancer Cohort of our CENDIFOX Trial - goo.gl/alerts/4TU3F1 Lisata Therapeutics, Inc. KU Cancer Center KU Hospital News PanCAN Let's Win Pancreatic Cancer 💜 #PancSM Chat Looking forward to the results in the near future !

Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile Photo

Thank you Binay Shah, MD, MHA for inviting me to discuss #Hepatobiliary and #pancreaticcancer updates from #ASCO24. It was an honor to present at such a well-organized and educational conference. #BestOfASCO @asco2024 Beyond Trauma Foundation #globaloncology KU Cancer Center

Thank you <a href="/binayshah/">Binay Shah, MD, MHA</a> for inviting me to discuss #Hepatobiliary and #pancreaticcancer updates from #ASCO24. It was an honor to present at such a well-organized and educational conference. #BestOfASCO @asco2024 <a href="/btfoundation/">Beyond Trauma Foundation</a>
#globaloncology <a href="/KUcancercenter/">KU Cancer Center</a>
Anup Kasi MD MPH (@anup_kasi) 's Twitter Profile Photo

Thrilled to speak at the #KUICE_T symposium on the role of #CAR_T in solid tumors! Huge thanks to Al-Ola A Abdallah MD (USMIRC) & Nausheen Ahmed MD for the invitation. The event was incredibly insightful, showcasing the latest in cellular therapeutics for hematology and oncology! KU Cancer Center

Thrilled to speak at the #KUICE_T symposium on the role of #CAR_T in solid tumors! Huge thanks to <a href="/Abdallah81MD/">Al-Ola A Abdallah MD (USMIRC)</a> &amp; <a href="/NausheenAhmedMD/">Nausheen Ahmed MD</a> for the invitation. The event was incredibly insightful, showcasing the latest in cellular therapeutics for hematology and oncology! <a href="/KUcancercenter/">KU Cancer Center</a>
OncoAlert (@oncoalert) 's Twitter Profile Photo

The AVENGER 500 trial Phase III global🌐study, investigated the efficacy and safety of adding devimistat to a modified regimen of fluorouracil, oxaliplatin, irinotecan🧪, and leucovorin for treating metastatic pancreatic adenocarcinoma (mPC). The trial involved 528

The AVENGER 500 trial
Phase III global🌐study, investigated the efficacy and safety of adding devimistat  to a modified regimen of fluorouracil, oxaliplatin, irinotecan🧪, and leucovorin for treating metastatic pancreatic adenocarcinoma (mPC).

The trial involved 528
Panavance (@panavance) 's Twitter Profile Photo

Dr. Anup Kasi will be presenting at the Visceral Medicine Conference in Leipzig, Germany on Oct. 4. This will be the first presentation of misetionamide (GP-2250) clinical results diving deeper into its Phase 1 trial to evaluate the safety, tolerability, and preliminary efficacy

Dr. Anup Kasi will be presenting at the Visceral Medicine Conference in Leipzig, Germany on Oct. 4. This will be the first presentation of misetionamide (GP-2250) clinical results diving deeper into its Phase 1 trial to evaluate the safety, tolerability, and preliminary efficacy
KU Cancer Center (@kucancercenter) 's Twitter Profile Photo

“We are delighted to complete enrollment in all three cohorts in the CENDIFOX study and are encouraged by certepetide’s potential to improve outcomes for patients with advanced solid tumors. We are eager to analyze the data from each cohort to determine the efficacy of this novel